What are the functions and effects of dasatinib?

Dasatinib is a highly effective anti-tumor drug, mainly used to treat patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) who are resistant or intolerant to imatinib mesylate. This drug plays an important role in the treatment of chronic myelogenous leukemia, especially in patients who have developed resistance or intolerance to the first-line treatment imatinib. Dasatinib provides a new treatment option.

Dasatinib inhibits the activity of BCR-ABL tyrosine kinase and blocks the BCR-ABL signaling pathway, thereby inhibiting the proliferation and survival of leukemia cells. BCR-ABL is an abnormal fusion gene common in chronic myelogenous leukemia, and its overactivation can lead to the malignant proliferation of leukemia cells. Dasatinib can selectively interfere with this signal transduction pathway and thereby control disease progression.

In addition, dasatinib also has inhibitory effects on other types of tyrosine kinases, including the SRC kinase family, EPHA2 and FDGFR, etc., which makes it show potential in the treatment of various types of leukemias and other tumors. For example, in patients with acute lymphoblastic leukemia (Ph+ALL), dasatinib can also control the disease by inhibiting tyrosine kinase activity and blocking the excessive activation of leukemia cells.

The clinical application of dasatinib shows that it can not only effectively inhibit the proliferation of leukemia cells, but also prolong the survival of patients, improve prognosis, and control disease progression. For patients with chronic myelogenous leukemia, dasatinib can significantly improve the overall survival rate and quality of life. In addition, dasatinib also has a certain immunomodulatory effect and helps restore the patient's normal hematopoietic function.

However, the use of dasatinib also requires attention to its potential side effects. Common side effects include bone marrow suppression (such as anemia, leukopenia and thrombocytopenia), gastrointestinal reactions (such as nausea, vomiting, diarrhea), fluid retention (such as pleural effusion, edema), etc. Therefore, during the use of dasatinib, patients need to closely monitor blood, liver and kidney function and other indicators, and follow the doctor's instructions to adjust the dose or deal with side effects in a timely manner.

Overall, dasatinib is an important anti-tumor drug that has demonstrated significant efficacy and potential in the treatment of chronic myelogenous leukemia and other types of leukemia. However, its use also needs to be carried out under the guidance of a doctor to ensure safe and effective disease control.